Ticker > Company >

Mercury Laboratories share price

Mercury Laboratories Ltd.

BSE: 538964 SECTOR: Pharmaceuticals & Drugs  12k   19   0

879.00
+41.25 (4.92%)
BSE: 13 Jun 04:01 PM

Price Summary

Today's High

₹ 889

Today's Low

₹ 829

52 Week High

₹ 1190

52 Week Low

₹ 736

FinStar

Ownership Stable
Ownership strength is slightly missing the benchmark.
ValuationExpensive
The stock is at a premium valuation at this point.
EfficiencyOptimal
The company could improve upon its asset employment.
FinancialsAverage
The company could improve upon its asset employment.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

105.48 Cr.

Enterprise Value

102.75 Cr.

No. of Shares

0.12 Cr.

P/E

33.54

P/B

1.97

Face Value

₹ 10

Div. Yield

0.4 %

Book Value (TTM)

₹  446.41

CASH

8.23 Cr.

DEBT

5.5 Cr.

Promoter Holding

73.66 %

EPS (TTM)

₹  26.21

Sales Growth

0.3%

ROE

11.72 %

ROCE

13.61%

Profit Growth

1.35 %

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.
* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year0.3%
3 Year3.27%
5 Year6.36%

Profit Growth

1 Year1.35%
3 Year1.94%
5 Year14.8%

ROE%

1 Year11.72%
3 Year11.31%
5 Year12.01%

ROCE %

1 Year13.61%
3 Year14.02%
5 Year15.17%

Debt/Equity

0.1081

Price to Cash Flow

12.82

Interest Cover Ratio

19.0687

CFO/PAT (5 Yr. Avg.)

1.26592008541303

Shareholding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Mar 2025 73.66 0.00
Dec 2024 73.66 0.00
Sep 2024 73.66 0.00
Jun 2024 73.66 0.00
Mar 2024 73.66 0.00
Investors List
* Figures given above are % of equity capital

 Strengths

  • Company has a healthy Interest coverage ratio of 19.0687.
  • The company has an efficient Cash Conversion Cycle of 32.2209 days.
  • Company has a healthy liquidity position with current ratio of 3.0777.
  • The company has a good cash flow management; CFO/PAT stands at 1.26592008541303.
  • The company has a high promoter holding of 73.66%.

 Limitations

  • The company has shown a poor profit growth of 1.93995230931054% for the Past 3 years.
  • The company has shown a poor revenue growth of 3.27234930109397% for the Past 3 years.

Quarterly Result (All Figures in Cr.)

PARTICULARS Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025
Net Sales 17.37 16.68 18.19 19.57 20.66
Total Expenditure 14.72 15.07 16.88 17.6 18.54
Operating Profit 2.65 1.61 1.31 1.98 2.12
Other Income 0.41 0.15 0.21 0.53 0.18
Interest 0.1 0.14 0.15 0.13 0.13
Depreciation 0.72 0.7 0.71 0.74 0.73
Exceptional Items 0 0 0 0 0
Profit Before Tax 2.25 0.92 0.65 1.64 1.45
Tax 0.34 0.58 0.15 0.45 0.34
Profit After Tax 1.91 0.34 0.5 1.19 1.11
Adjusted EPS (Rs) 15.92 2.85 4.18 9.93 9.25

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Net Sales 57.27 68.6 57.92 75.33 75.56
Total Expenditure 51.1 59.01 50.93 66.76 66.53
Operating Profit 6.17 9.59 6.99 8.57 9.03
Other Income 0.85 0.88 0.82 1.72 1.09
Interest 0.82 0.64 0.45 0.36 0.38
Depreciation 1.87 1.92 2.45 2.48 2.82
Exceptional Items 0 0 0.13 0 0
Profit Before Tax 4.33 7.91 5.03 7.44 6.92
Tax 1.1 2.57 1.47 1.87 1.27
Net Profit 3.23 5.34 3.56 5.58 5.65
Adjusted EPS (Rs.) 26.9 44.48 29.68 46.49 47.12

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Equity and Liabilities
Share Capital 1.2 1.2 1.2 1.2 1.2
Total Reserves 30.78 35.69 39.11 44.43 49.64
Borrowings 6.33 6.24 2.49 2.42 2.86
Other N/C liabilities 2.93 3.4 3.89 1.94 1.31
Current liabilities 15.07 18.83 15.75 14.18 12.94
Total Liabilities 56.3 65.37 62.43 64.16 67.96
Assets
Net Block 23.66 26.36 25.82 24.26 24.03
Capital WIP 0 0 0 0.13 3.82
Intangible WIP 0 0 0 0 0
Investments 0.01 0.01 0.01 0.01 0.01
Loans & Advances 0 0 0 0 0
Other N/C Assets 1.12 1.21 1.39 0.31 0.27
Current Assets 31.51 37.8 35.22 39.46 39.84
Total Assets 56.3 65.37 62.43 64.16 67.96
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Profit from operations 4.33 7.91 5.03 7.44 6.92
Adjustment 2.69 2.56 2.88 2.85 3.2
Changes in Assets & Liabilities -0.3 -0.89 -0.8 -6.73 -0.64
Tax Paid -1.23 -1.37 -1.91 -1.1 -1.26
Operating Cash Flow 5.49 8.21 5.19 2.45 8.23
Investing Cash Flow -1.14 -4.62 -1.89 -1.06 -6.27
Financing Cash Flow -3.33 -1.24 -1.23 -1.01 -1.04
Net Cash Flow 1.02 2.36 2.07 0.38 0.91

Corporate Actions

Investors Details

PARTICULARS Mar 2024% Jun 2024% Sep 2024% Dec 2024% Mar 2025%
promoters 73.66 73.66 73.66 73.66 73.66
adit dilipbhai shah 1.29 1.29 1.29 1.29 1.29
bimal ramanlal shah 1.17 1.17 1.17 1.17 1.17
dilip ramanlal shah 7.07 7.07 - 7.07 7.07
janki rajendra shah 8.67 8.67 - 8.67 8.67
kaumudini rajendra shah... 1.76 1.76 - 1.76 1.76
kishoriben dilip shah 0.28 0.28 - 0.28 0.28
paresh ramanlal shah 1.97 1.97 1.97 1.97 1.97
parulben kiranbhai laliwa... 1.02 1.02 1.02 1.02 1.02
rajendra ramanlal shah 7.14 7.14 - 7.14 7.14
shah dilip ramanlal huf... 25.88 25.88 25.88 25.88 25.88
shah rajendra ramanlal ... - - - - 17.42
shah rajendra ramanlal ... 17.42 17.42 - 17.42 -
dilip ramanlal shah - - 7.07 - -
janki rajendra shah - - 8.67 - -
kaumudini rajendra shah - - 1.76 - -
kishoriben dilip shah - - 0.28 - -
rajendra ramanlal shah - - 7.14 - -
shah rajendra ramanlal hu... - - 17.42 - -
PARTICULARS Mar 2024% Jun 2024% Sep 2024% Dec 2024% Mar 2025%
investors 26.34 26.34 26.34 26.34 26.34
bharati bharat dattani 1.64 1.64 1.64 1.64 1.64
investor education and pr... - - 6.01 6.29 6.29
ketan babulal shah 1.23 1.23 1.23 1.23 1.23
rajeshri ketan shah - - - - 2.20
sharad kanayalal shah 1.11 1.11 1.11 1.11 1.11
rajeshri k shah 2.20 2.20 2.20 2.20 -
investor education and pr... 6.01 6.01 - - -

Annual Reports

Title Action
Annual Report 2021
Annual Report 2020
Annual Report 2019
Annual Report 2018
Annual Report 2017
Annual Report 2017

Ratings & Research Reports

TYPE AGENCY ACTION
Credit CRISIL
Credit CRISIL
Credit CRISIL
TYPE AGENCY ACTION
No Research reports exist for this company.Report us

Concalls & Presentations

TYPE QUARTER ACTION
Currently we do not have any Concall related to this company.Report us
TYPE QUARTER ACTION
Currently we do not have any Presentation related to this company.Report us

Company News

 No Latest News available for this company.
Report us

Mercury Laboratories Stock Price Analysis and Quick Research Report. Is Mercury Laboratories an attractive stock to invest in?

The Indian healthcare sector is expected to reach US$ 372 billion by 2022, driven by rising incomes, greater health awareness, lifestyle diseases and increasing access to insurance. Healthcare has become one of India’s largest sectors - both in terms of revenue and employment.

Healthcare comprises hospitals, medical devices, clinical trials, outsourcing, telemedicine, medical tourism, health insurance, and medical equipment. The structure of the healthcare delivery system in India consists of three broad segments: Primary care, Secondary care, and Tertiary care.

  • Primary care is the first point of contact between the population and the healthcare service providers. For example, Sub-center (SC), Primary Health Centre (PHC) and Community Health Centre (CHC) which is more relevant to rural areas (PHC’s).
  • Secondary care providers inpatient as well as outpatient medical services and includes simple surgical procedures. For example, District level & Mid-sized hospitals.
  • Tertiary care is the third level of the healthcare delivery system in the country. These hospitals are specialized consultative healthcare infrastructure. For example, Single specialty and Multi-specialty hospitals.

While healthcare services are offered by the public as well as private sectors, in urban as well as rural areas, generally people prefer private hospitals over public hospitals for treatment of diseases, illness, and sickness. So, let’s look into Mercury Laboratories and its performance over the period of time. Mercury Laboratories stock price today is Rs 879.

  • Operating cash flow ratio: It measures the adequacy of a company’s cash generated from operating activities to pay off short-term financial obligations. Mercury Laboratories cash from the operating activity was Rs 8.225 Cr.
     
  • Financial Strength: Health care organizations usually have high debt loads and low equity capital in their balance sheet. So, Debt to Equity ratio is important to analyze the company’s sustainability. Mercury Laboratories has a Debt to Equity ratio of 0.1081 , which is a strong indication for the company.
     
  • EPS growth: Investors should ensure the EPS figure is growing faster than revenue numbers because it indicates company management is increasing the efficiency with which it runs the company. In Mercury Laboratories , the EPS growth was 1.3515 % which is bad for the company.
     
  • Operating profit margin: It determines a company's potential earnings. It assesses how well-managed a company with respect to its basic overhead costs and other operating expenses, Mercury Laboratories has OPM of 11.9513228073426 % which is a bad sign for profitability.
     
  • ROE: Mercury Laboratories have a average ROE of 11.7225 %. ROE is an important financial parameter for hospitals & health care companies because they expand and grow rapidly. Therefore, ROE measures how efficiently a shareholder's fund is used for generating profits.
     
  • Share Price: - The current share price of Mercury Laboratories is Rs 879. One can use valuation calculators of ticker to know if Mercury Laboratories share price is undervalued or overvalued.
Last Updated on:
Brief about Mercury Laboratories
X